A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


December 7, 2007

Tesamorelin KO’s Belly Fat

Treatment with the synthetic human growth hormone-releasing factor, tesamorelin, resulted in a significant loss of visceral adipose tissue—deep belly fat—compared with a placebo in people with lipodystrophy, according to a new article published in the December 6 issue of the New England Journal of Medicine (NEJM).

The tesamorelin study is a 52-week trial involving 412 patients with lipodystrophy. During the first 26 weeks, 273 patients received tesamorelin and 137 received a placebo. During the second 26 weeks of the study, those who’d originally received placebo switched to tesamorelin, while those who originally received tesamorelin either stayed on the drug or were switched to placebo.

In the NEJM article, Julian Falutz, MD, of the Montreal General Hospital at the McGill University Health Centre, and his colleagues report the results from the first 26 weeks of the study. At week 26, those who’d received tesamorelin had a 15.2 percent decrease in visceral adipose tissue, compared with a 5 percent increase in those who received a placebo. Moreover, people in the tesamorelin group had greater improvements in cholesterol and insulin function than those who received a placebo.

There was no difference in the incidence of serious side effects between those receiving tesamorelin or placebo. However, those taking tesamorelin were more likely to discontinue the drug due to side effects than those in the placebo group.

Preliminary data from the second half of the study were reported at the 2007 European AIDS Conference in Madrid. Final results from the 52-week study have not yet been published in a peer-reviewed medical journal.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (22 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.